A New Frontier for Flu: Moderna’s mRNA Vaccine Outperforms Standard Shots in Large-Scale Trial

CAMBRIDGE, MA — In a milestone for respiratory medicine, Moderna announced today that its experimental mRNA-based influenza vaccine, mRNA-1010, significantly outperformed traditional flu shots in a massive Phase 3 clinical trial. The study, published May 6, 2026, in the New England Journal of Medicine, found that the mRNA candidate reduced the risk of influenza-like illness by approximately 27% compared to standard-dose vaccines in adults aged 50 and older.

The trial, known as P304, involved more than 40,000 participants across 11 countries. The findings suggest that the same messenger RNA technology that transformed the global response to COVID-19 may finally solve a decades-old problem: the stubborn inefficiency of seasonal flu vaccines, particularly in older populations whose immune systems often mount a weaker response to traditional injections.

Breakthrough Findings: Better Protection Across All Strains

The primary goal of the trial was to measure “relative vaccine efficacy” (rVE)—essentially, how much better the new shot works compared to the one currently available at most local pharmacies.

The results were consistent across the board. In adults 50 and older, the mRNA vaccine demonstrated a 26.6% higher relative efficacy over the standard-dose comparator. Crucially, this protection held firm against the three major circulating strains of the virus:

• A/H1N1: 29.6% rVE

• A/H3N2: 22.2% rVE

• B/Victoria: 29.1% rVE

Among the most vulnerable subgroup—those aged 65 and older—the vaccine maintained a robust 27.4% relative efficacy. For context, traditional egg-based vaccines often see their effectiveness dip significantly in this age bracket, sometimes falling below 40% in years where the vaccine “match” is poor.

“mRNA flu vaccines don’t just change how we make the shot; they may change how well it protects, especially in older adults,” said Dr. Angela Rasmussen, a virologist who was not involved in the trial. “If real-world effectiveness mirrors these trial results, this could be a meaningful step forward for flu prevention.”

The “Egg” Problem: Why mRNA is Different

For over 70 years, most flu vaccines have been produced by growing viruses in chicken eggs. While reliable, this method is slow and prone to “egg-adaptation.” As the virus grows in the egg, it can mutate slightly, meaning the final product may no longer perfectly match the virus circulating in the community.

mRNA-1010 bypasses this biological middleman. Instead of using a weakened or killed virus, it uses a synthetic strand of genetic code that teaches human cells to produce the flu’s hemagglutinin protein. The immune system then builds a “defense manual” against that specific protein.

This platform offers two distinct advantages:

1. Speed: mRNA sequences can be updated in weeks rather than months, allowing scientists to wait longer into the year to see which flu strains are actually dominant before finalizing the recipe.

2. Precision: Because it is not grown in eggs, the vaccine remains a “pure” match to the target virus, potentially leading to the stronger antibody responses seen in the Moderna data.

Public Health: The Power of Small Percentages

At first glance, a 27% improvement might seem modest. However, in the world of public health, such a shift is monumental.

The Centers for Disease Control and Prevention (CDC) estimates that seasonal flu causes tens of thousands of deaths and hundreds of thousands of hospitalizations in the United States annually. Dr. William Schaffner, a preventive-medicine specialist at Vanderbilt University, notes that even small gains in efficacy can prevent a massive number of clinical visits.

“If you can push flu vaccine effectiveness from roughly 50% up toward the low-60s or higher in older adults, that’s meaningful at a population level,” Dr. Schaffner explained. “It may not sound like a huge jump, but even modest improvements can spare many hospitalizations over a season.”

Comparison of Vaccine Platforms

Safety and Side Effects

For consumers concerned about “reactogenicity”—how the body feels immediately after the shot—the trial offered reassuring data. Side effects were predominantly mild to moderate.

The most common reported issues included:

• Injection-site pain

• Temporary fatigue

• Short-term muscle aches

These symptoms occurred at rates similar to those seen with currently licensed flu vaccines. Serious adverse events were rare and did not occur more frequently in the mRNA group than in the group receiving the standard shot.

Limitations: A “Progress, Not a Final Solution”

Despite the optimism, researchers and independent experts urge a balanced view. The trial represents a “snapshot” of a single flu season. Because the flu virus is a moving target that changes every year, the vaccine’s performance must be monitored over multiple seasons to ensure these gains are consistent.

Dr. Scott Hensley, an influenza immunologist at the University of Pennsylvania, cautioned in prior commentary that while this is a leap forward, it isn’t a “silver bullet.”

“This is progress, not a final solution,” Dr. Hensley noted. “We’ll still need good surveillance, smart strain-selection decisions, and broad vaccination coverage to keep the flu burden down.”

Furthermore, Moderna has not yet specified the exact brands used as comparators in the trial, and the logistical challenges of mRNA vaccines—such as stricter cold-storage requirements—remain a hurdle for global distribution in low-resource settings.

What Happens Next?

Moderna has signaled its intent to seek regulatory approval quickly, with an eye toward making the vaccine available for the 2026–2027 flu season in the United States and other major markets.

For the average person, this doesn’t change the advice for the current season: The best flu shot is the one you can get today. However, by this time next year, “health-conscious” may mean choosing between a traditional shot and a high-tech mRNA alternative that offers a bit more “muscle” against the winter’s most common respiratory threat.

References

1. Moderna, Inc. (2026). Publication of Phase 3 Results for mRNA-1010 in the New England Journal of Medicine. Press Release.

2. https://www.reuters.com/legal/litigation/modernas-mrna-flu-vaccine-outperforms-standard-shot-late-stage-trial-2026-05-06/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.